Equillium to Host May 27 Webinar Revealing AhR Modulator and miR-124 Findings
Equillium will host a May 27 webinar at 11:00 AM ET to unveil preclinical data on AhR modulators and their mechanistic link to miR-124 induction. The findings guide development of EQ504, a selective AhR modulator engineered for enteric-coated ulcerative colitis treatment and inhaled lung inflammation therapy.
1. Webinar Agenda and Focus
Equillium will present at 11:00 AM ET on May 27 new preclinical evaluations of clinically relevant AhR modulators and detailed characterization of the paradoxical AhR/miR-124 axis in immune and epithelial cells. Dr. Stephen Connelly will discuss ligand-dependent AhR signaling cascades, miR-124 induction patterns, and their role in inflammation modulation, followed by a live Q&A session with management.
2. EQ504 and Mechanistic Applications
The insights aim to establish a unifying mechanistic framework linking AhR activation to miR-124 regulation, clarifying conflicting data on miR-124's inflammatory effects. These findings will inform development of EQ504, a selective AhR modulator engineered for enteric coating in ulcerative colitis and inhaled formulations targeting inflammatory lung diseases.